Regeneron Beats Q1 Estimates, But Stock Slips on Margin Headwinds and Manufacturing Glitch
Regeneron Pharmaceuticals (NASDAQ:REGN) reported a strong first quarter that topped analyst expectations on both the top and bottom lines, driven by surging sales of its newer products and robust collaboration revenue from Dupixent. Despite the beat, shares moved lower in pre-market trading, reflecting investor concerns over a temporary manufacturing disruption that is squeezing gross margins and a narrowed full-year profit outlook.
Earnings Recap: Beating the Street
The company posted non-GAAP earnings per share (EPS) of $9.47 for the quarter ended March 31, 2026, surpassing the consensus estimate of $9.07. On a reported GAAP basis, EPS came in at $6.75, a decline from the $7.27 reported in the same period last year, largely due to a $0.82 per-share negative impact from in-process research and development (IPR&D) charges.
Total revenue for the quarter reached $3.61 billion, a 19% increase year-over-year and comfortably ahead of the analyst forecast of $3.55 billion.
Key Financial Highlights (Q1 2026 vs. Q1 2025)
- Total Revenue: $3.61 billion (up 19%).
- Non-GAAP Net Income: $1.04 billion (up 12%).
- Non-GAAP Diluted EPS: $9.47 (up 15%).
- GAAP Diluted EPS: $6.75 (down 7%).
- Net Product Sales: $1.53 billion (up 8%).
What Drove the Quarter?
A deep dive into the revenue components reveals a mixed picture, with a star performer in the pipeline but a legacy product in transition.
Product Sales & Pipeline Progress
- EYLEA HD: The star of the show. U.S. net sales surged 52% to $468 million, driven by higher demand. The FDA recently approved an extension of its dosing interval to up to five months for wet AMD and DME, a significant competitive advantage.
- EYLEA (legacy): As expected, sales dropped 36% to $473 million as patients continue to transition to the higher-dose EYLEA HD. Combined U.S. sales of both products fell 10% to $941 million.
- Libtayo: Global sales jumped 54% to $438 million, fueled by strong demand in both the U.S. and rest of world.
- Dupixent: While not a direct product sale for Regeneron, its share of profits from the Sanofi collaboration soared. Dupixent global net sales (recorded by Sanofi) increased 33% to $4.9 billion, translating into a 36% jump in Sanofi collaboration revenue for Regeneron, which hit $1.61 billion.
Beyond the numbers, the quarter was marked by significant regulatory wins. The FDA approved Otarmeni, the first-ever gene therapy for genetic hearing loss, and expanded approvals for Dupixent in chronic spontaneous urticaria and allergic fungal rhinosinusitis.
The Red Flag: Margin Pressure and a Revised Outlook
While revenues and EPS were strong, the market's negative reaction appears tied to cost pressures and a lowered profitability forecast. The main culprit is a temporary interruption in bulk manufacturing at the company's Limerick, Ireland facility, which started in Q1 and has led to unabsorbed costs and higher inventory write-offs.
This caused the GAAP gross margin on product sales to contract to 76% (from 81% a year ago). Consequently, Regeneron revised its full-year 2026 guidance:
- GAAP Gross Margin: Cut to 77%–78% from a prior range of 79%–80%.
- GAAP COCM (Cost of Collaboration & Contract Manufacturing): Increased to $955 million–$1.035 billion.
The company noted it resumed production in Q2 and expects margins to normalize by the end of the second quarter, but the near-term impact is evident. On a positive note, non-GAAP gross margin guidance remains solidly in the 83%–84% range, and management left its R&D and SG&A spending forecasts unchanged.
Shareholder Returns
Management continues to reward investors. During the quarter, the company repurchased $803 million of its common stock. In April, the board authorized a new $3.0 billion share repurchase program. The company also declared a quarterly cash dividend of $0.94 per share.
Market Reaction
The stock’s pre-market decline of approximately 1.3% suggests that the revenue beat and strong sales of EYLEA HD and Libtayo were not enough to offset the sting of the lowered gross margin guidance stemming from the manufacturing hit. The market is likely pricing in the risk of continued margin pressure until the Ireland facility fully ramps back up.
Looking Ahead: Analyst Estimates and Guidance
Regeneron’s updated guidance did not provide a specific full-year revenue or EPS target, but the revised margin forecast is the key takeaway. For the next quarter, analysts are expecting revenue of approximately $3.89 billion and non-GAAP EPS of roughly $10.84. For the full fiscal year 2026, the consensus is currently calling for over $16 billion in sales and an EPS of nearly $47.
Want to dig deeper into the numbers?
You can review all of REGENRON PHARMACEUTICALS (NASDAQ:REGN) historical earnings reports, future projections, and detailed analyst estimates on our dedicated platforms:
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.